stella
Condition Guide

New Treatments & Clinical Trials for Metabolic Syndrome

Last updated July 2026Data from ClinicalTrials.gov0 active trials
← Browse all Metabolic Syndrome trials

Metabolic syndrome is a cluster of conditions — high blood pressure, high blood sugar, excess abdominal fat, and abnormal cholesterol — that together raise the risk of heart disease, stroke, and type 2 diabetes. About one in three U.S. adults has metabolic syndrome. Treatment focuses on lifestyle changes and medications to address each component.

What's actually going on in research

Trials are testing GLP-1 receptor agonists like semaglutide for weight loss and metabolic improvement, SGLT2 inhibitors for cardiovascular protection, drugs targeting inflammation and fatty liver disease, and combination approaches that address multiple pathways at once. Researchers are also studying how gut bacteria, sleep, and specific dietary patterns affect metabolic health.

GLP-1 receptor agonists

Drugs like semaglutide and tirzepatide produce substantial weight loss and improve blood sugar, blood pressure, and cholesterol. Trials are testing whether they can prevent progression to diabetes and reduce heart attacks.

NASH and liver-targeted therapies

Many people with metabolic syndrome develop fatty liver disease. New drugs targeting liver inflammation and fibrosis are in late-stage trials, some showing reversal of liver damage.

Microbiome interventions

Studies are testing whether changing gut bacteria through specific prebiotics, probiotics, or dietary interventions can improve insulin sensitivity and reduce inflammation. Early results suggest the gut may be a key lever for metabolic health.

What to know before you search

Eligibility typically depends on having at least three of the five metabolic syndrome criteria, BMI, presence of fatty liver or prediabetes, and cardiovascular risk factors.

What types of trials are currently open

  • Weight loss trialsTesting medications, often GLP-1 drugs or combination therapies, to produce sustained weight loss and metabolic improvement.
  • Cardiovascular outcome trialsFollowing people for years to see if a treatment reduces heart attacks, strokes, and death in those with metabolic syndrome.
  • Liver disease trialsTesting drugs for nonalcoholic fatty liver disease and NASH, common in metabolic syndrome.
  • Lifestyle intervention trialsComparing different diet, exercise, or sleep strategies to see which combinations work best for reversing metabolic syndrome.
  • Prevention trialsTesting whether early treatment with medication or intensive lifestyle changes can prevent progression to diabetes or cardiovascular disease.

Recently added Metabolic Syndrome trials

RecruitingInterventional study

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study. The main question is: Does the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone? The study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety. Researchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support. Participants in both groups will: * Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol. * Photograph everything they eat and drink. * Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study. * Be able to view the results of the food photograph analysis. The photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.

Almaty, Kazakhstan
RecruitingInterventional study

Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease

metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem

Giza, Dokki, Egypt
See all recruiting Metabolic Syndrome trials →

Find Metabolic Syndrome trials matched specifically to you

Answer 3 quick questions and we'll show you trials that fit your situation.

Get matched →